<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; experts</title>
	<atom:link href="http://www.tapanray.in/tag/experts/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>China Relaxes Drug Price Control: Is Pharma Euphoria In India Misplaced?</title>
		<link>http://www.tapanray.in/china-relaxes-drug-price-control-is-pharma-euphoria-in-india-misplaced/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-relaxes-drug-price-control-is-pharma-euphoria-in-india-misplaced</link>
		<comments>http://www.tapanray.in/china-relaxes-drug-price-control-is-pharma-euphoria-in-india-misplaced/#comments</comments>
		<pubDate>Mon, 01 Jun 2015 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[domain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Euphoria]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[National Development and Reform Commission]]></category>
		<category><![CDATA[National Health Policy]]></category>
		<category><![CDATA[NDRC]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relaxes]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal Health Care]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6695</guid>
		<description><![CDATA[On May 5, 2015, the National Development and Reform Commission (NDRC) of China announced that price controls on most drugs sold there would be lifted from June 1, 2015. This move was believed to tackle issues of drug quality and &#8230; <a href="http://www.tapanray.in/china-relaxes-drug-price-control-is-pharma-euphoria-in-india-misplaced/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-relaxes-drug-price-control-is-pharma-euphoria-in-india-misplaced/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make Global Pharma Responsible in Homeland for Objectionable Conduct in Clinical Trials Elsewhere”</title>
		<link>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere</link>
		<comments>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/#comments</comments>
		<pubDate>Wed, 12 Feb 2014 01:30:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Azad]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Desiraju]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[Ghulam]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[keshav]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Nabi]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[objectionable]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[secretary]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4988</guid>
		<description><![CDATA[In the context of his recent meeting with Commissioner Margaret A. Hamburg of US-FDA, the Drug Controller General of India (DCGI) reportedly expressed his concern to ‘The Economic Times’ on the ‘objectionable conduct’ of global pharma in new drug trials &#8230; <a href="http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-global-pharma-responsible-in-homeland-for-objectionable-conduct-in-clinical-trials-elsewhere/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New ‘Patient Compensation’ Norms on Clinical Trials in India: Overdue Action, Sharp Reaction and Ethical Issues</title>
		<link>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues</link>
		<comments>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/#comments</comments>
		<pubDate>Mon, 25 Feb 2013 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[controlled]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[GSR]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[negligence]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reaction]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1996</guid>
		<description><![CDATA[Responding to the damning stricture made by the Supreme Court on January 3, 2013, the Ministry of Health, as expected, by a gazette notification of January 30, 2013 has made the norms of compensation to patients participating in Clinical Trials &#8230; <a href="http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
